CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
FlexiBiome offers a standardized mixture of living bacteria as a safer and more effective alternative to fecal microbiota therapy for treating recurrent Clostridium difficile infections. This product aims to simplify treatment and reduce costs while ensuring consistent quality.
PharmaBiome AG is an ETH Zurich spin-off company that was established in February 2015 after intense scientific interactions at ETH Zurich between highly qualified scientists and business professionals in the fields of biotechnology and gastroenterology.
We envisioned a huge interest of the pharmaceutical industry in microbiome-based technologies.Our primary target market focuses on patients suffering from recurrent Clostridium difficile infections (rCDI), which are usually a consequence of anti…
PHARMABIOME AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
